A Study of PF-04217903 in Patients With Advanced Cancer

Pfizer

Status and phase: Terminated; Phase 1

Conditions: Neoplasms

Treatments: Drug: PF-04217903

Study type: Interventional

Funder types: Industry

Identifiers

NCT00706355

B0331002

Details and patient eligibility

About

PF-04217903 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-04217903 is a new member in a class of drugs called c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitors. This research study is the first time PF-04217903 will be given to patients. PF-04217903 is taken by mouth daily.

Full description

The study was prematurely discontinued due to a strategic development decision by Pfizer on 10FEB2012. The decision to terminate was not based on any safety concerns.

Enrollment: 16 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced solid tumors, histologically proven at diagnosis which is refractory to standard of care or for whom no standard of care therapy is available
• Adequate blood cell counts, normal kidney function, and performance status of 0 or 1

Exclusion criteria

• Major surgery, radiation therapy or anti-cancer therapy within 2 weeks of starting study treatment
• Prior stem cell transplant
• Active or unstable cardiac disease or heart attack within 12 months of starting study treatment

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

16 participants in 1 patient group

1

Experimental group

Treatment:

Drug: PF-04217903